Pfizer Inc (CHIX:PFEd)

€ 26.895 0.38 (1.43%) Market Cap: 152.52 Bil Enterprise Value: 208.39 Bil PE Ratio: 0 PB Ratio: 1.95 GF Score: 71/100

Q2 2024 Pfizer Inc Earnings Call Transcript

Jul 30, 2024 / 02:30PM GMT

Release Date Price: €28.61 (+1.20%)

Transcript 10-Q8-K

Key Points

Positve

Pfizer Inc (PFE) reported strong financial results for the second quarter of 2024, achieving year-over-year revenue growth for the first time since Q4 2022.
The company reached over 192 million patients with its medicines and vaccines in the first half of 2024.
Pfizer Inc (PFE) raised its full-year 2024 guidance ranges for revenue and adjusted diluted earnings per share.
The integration of Seagen's products is progressing well, with high rates of colleague retention and meaningful revenue contributions.
Significant progress in the oncology portfolio, including full FDA approval for Tivdak and European Medicines Agency approval for the Talzenna plus Xtandi combination.

Negative

The departure of Mikael Dolsten, Chief Scientific Officer and President of R&D, may impact the company's R&D momentum.
The company faces challenges in the adult pneumococcal vaccine market in the US due to a shrinking eligible population.
Pfizer Inc (PFE) is dealing with the impact of the Inflation Reduction Act (IRA) on its revenue outlook for 2025 and 2026.
The company expects operating cash flows to be significantly below typical levels in 2024 due to the timing of certain payments and one-time expenses.
The market for Paxlovid is highly dependent on COVID infection rates, which introduces variability in revenue.

Operator

Good day, everyone, and welcome to Pfizer's second-quarter 2024 earnings conference call. Today's call is being recorded.

At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.

Francesca DeMartino

Pfizer Inc - Chief Investor Relations Officer, Senior Vice President

Good morning, and welcome to Pfizer's earnings call. I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the second quarter of 2024 via a press release that is available on our website at pfizer.com.

I'm joined today by Dr. Albert Bourla, our Chairman and CEO; and Dave Denton, our CFO. Albert and Dave have some prepared remarks, and we will then open the call for questions. Joining for the Q&A session, we also have Dr. Chris Boshoff, EVP and Chief Oncology Officer; Alexandre de Germay, EVP and Chief

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.